Basics of cancer immunotherapy

• Published in: Rinshō ketsueki Vol. 57; no. 11; p. 2346
• Main Authors: Fujioka, Yuki, Nishikawa, Hiroyoshi
• Format: Journal Article
• Language: Japanese
• Published: Japan 2016
• Subjects: Animals; Antigens - immunology; Biomarkers, Tumor - immunology; Humans; Immunotherapy; Neoplasms - immunology; Neoplasms - therapy; T-Lymphocytes, Regulatory - immunology
• ISSN: 0485-1439
• DOI: 10.11406/rinketsu.57.2346

The immune system is the body's defense against infectious organisms and other invaders including cancer cells. Cancer immunotherapy, which employs our own immune systems to attack cancer cells, is now emerging as a promising modality of cancer treatment based upon the clinical successes of immune checkpoint blockade and adoptive T cell transfer. In hematologic malignancies, clinical application of anti-PD-1 mAb and CAR (chimeric antigen receptor) T therapy is now being extensively tested in Hodgkin's disease, multiple myeloma, and CD19
acute lymphocytic leukemia. In sharp contrast to conventional anti-cancer reagents which directly kill cancer cells, cancer immunotherapy activates various types of immune effector cells to attack cancer cells. However, more than half of the treated patients showed no activation of anti-tumor CD8
killer T cells and CD4
helper T cells and failed to respond to immune therapies such as immune checkpoint blockade, even when administered in combination regimens. Thus, development of novel immunotherapies to achieve more effective activation of anti-cancer immunity and immuno-monitoring of biomarkers, allowing proper evaluation of immune responses in cancer patients in order to detect responders, are urgent issues. Additionally, we must pay attention to characteristic immunological side effects not observed following treatment with conventional anti-cancer reagents. Herein, we present a summary outline and discuss the future direction of cancer immunotherapy.